The Britain-based drug developer originally expected to start a Phase 3 trial later this year and bring the drug to the market in 2020.
Now, the company must complete a new dose-ranging study, planned for 2017, before advancing to a Phase 3 trial.
Allergy Therapeutics, which specializes in allergy vaccines, will meet with the Food and Drug Administration later this year to discuss the drug.
This is the second allergy drug study to recently run into complications — Chicago-based Circassia Pharamceuticals’ cat allergy treatment failed in a late-stage trial two weeks ago.
More articles on supply chain:
Leukocyte reduction devices recalled for faulty filters
How Britain’s exit from the EU will affect the drug market
Natco Pharma earns FDA approval for ulcer drug
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
